InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Device hybrid approval not the same as substance authorisation, rules CJEU

Patrick Wingrove, London

In a decision that will disappoint medical device manufacturers, the CJEU in the Boston Scientific case has addressed the authorisation that must form the basis of an SPC. This is in contrast to recent referrals that address what products can be protected

CJEUIn a new supplementary protection certificate (SPC) development, the CJEU has ruled that the authorisation procedure for a pharmaceutical medical-device hybrid cannot be treated as an authorisation procedure for the substance.

In its judgment on the Boston Scientific case (C-527/17),...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null

null null null


November / December 2018

The 50 most influential people in IP

Managing IP reveals our pick of the people driving intellectual property law, policy and business this year. Read the full list here

Most read articles